Does LUSPATERCEPT-AAMT Cause Malignant neoplasm progression? 8 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 8 reports of Malignant neoplasm progression have been filed in association with LUSPATERCEPT-AAMT. This represents 0.5% of all adverse event reports for LUSPATERCEPT-AAMT.
8
Reports of Malignant neoplasm progression with LUSPATERCEPT-AAMT
0.5%
of all LUSPATERCEPT-AAMT reports
2
Deaths
2
Hospitalizations
How Dangerous Is Malignant neoplasm progression From LUSPATERCEPT-AAMT?
Of the 8 reports, 2 (25.0%) resulted in death, 2 (25.0%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LUSPATERCEPT-AAMT. However, 8 reports have been filed with the FAERS database.
What Other Side Effects Does LUSPATERCEPT-AAMT Cause?
Death (162)
Haemoglobin decreased (98)
Fatigue (86)
Off label use (85)
Weight decreased (76)
Dizziness (64)
Product storage error (64)
Drug ineffective (58)
Dyspnoea (52)
Fall (51)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which LUSPATERCEPT-AAMT Alternatives Have Lower Malignant neoplasm progression Risk?
LUSPATERCEPT-AAMT vs LUTEIN
LUSPATERCEPT-AAMT vs LUTETIUM LU-177
LUSPATERCEPT-AAMT vs LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
LUSPATERCEPT-AAMT vs LUTETIUM OXODOTREOTIDE LU-177
LUSPATERCEPT-AAMT vs LUTROPIN ALFA